GlassScriptPhysician profile
Sathya Jaganmohan
NPI 1922202597
$25,032.54
in general payments reported to CMS, 2019-2025
33 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,665 · 2021: $731 · 2022: $1,342 · 2023: $1,709 · 2024: $966 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,840 · Travel and Lodging: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.37 |
| Travel and Lodging | $703.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13,771.82 | 2019-2025 | Exalt Model D, Spyglass, General - Hemostasis |
| Abbvie INC. | $7,354.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $685.42 | 2019-2024 | Xifaxan, Trulance |
| Ovesco Endoscopy USA, INC. | $479.32 | 2023 | |
| Celgene Corporation | $352.14 | 2021-2024 | Zeposia |
| Ethicon US, LLC | $300.03 | 2021-2022 | |
| Micro-Tech Endoscopy USA, INC. | $258.34 | 2024 | |
| Genzyme Corporation | $221.50 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.48 | 2019-2022 | |
| Covidien LP | $163.15 | 2019 | |
| Evoke Pharma, INC. | $154.47 | 2022 | |
| Ambu INC. | $141.35 | 2020-2021 | |
| Pfizer INC. | $126.54 | 2019-2025 | |
| Vivus LLC | $93.65 | 2022-2023 | Qsymia |
| Cook Medical LLC | $89.26 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $72.08 | 2021-2024 | Barrx, Sharkcore |
| Gilead Sciences, INC. | $68.33 | 2025 | |
| Qol Medical, LLC | $65.13 | 2023-2024 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $62.13 | 2019-2025 | Tremfya |
| Pentax of America, INC. | $60.24 | 2022 | |
| Braintree Laboratories, INC. | $56.35 | 2019 | |
| Merck Sharp & Dohme LLC | $41.08 | 2021-2023 | Dificid |
| Novo Nordisk INC | $37.03 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $36.03 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $28.67 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.51 | 2022 | |
| Amgen INC. | $17.94 | 2025 | Uplizna |
| Celltrion USA INC. | $17.07 | 2024 | Vegzelma |
| Daiichi Sankyo INC. | $14.97 | 2019 | |
| Conmed Corporation | $14.69 | 2024 | Conmed Biliary |
| Lilly USA, LLC | $14.33 | 2024 | Omvoh |
| Shire North American Group INC | $13.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sathya Jaganmohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.